Friday, August 20th, 2021

Topical proteasome inhibitor promising for rosacea treatment

Topical ACU-D1 was safe, well tolerated and efficacious in treating rosacea, according to a phase 2a study published in the Journal of Drugs in Dermatology. ACU-D1 (pentaerythritol tetrakis (3-(3, 5-di-tert-butyl-4-hydroxyphenyl) propionate), a novel topical proteasome inhibitor, was compared with vehicle in the two-center, randomized, double-blinded, 14-week trial. “Rosacea is a common disorder of unknown origin,


Tuesday, August 17th, 2021

Study examines risk factors for systemic lupus erythematosus development.

Among patients with lupus erythematosus panniculitis resulting from cutaneous lupus erythematosus, male sex anddiscoid lupus erythematosus were risk factors for systemic lupus erythematosus development, according to a study. “Lupus erythematosus panniculitis (LEP) occurs in 1% to 3% of patients with cutaneous lupus erythematosus (CLE),” Juliette Lemasson, MD, of the dermatology service at Hôpital Saint-Louis in Paris, and colleagues wrote. “LEP


Tuesday, August 17th, 2021

Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis

Photodynamic therapy with aminolevulinate and imiquimod are among the treatments with good long-term efficacy for actinic keratosis, according to an investigation published in JAMA Dermatology. “Actinic keratoses (AK) are common precancerous lesions of the skin as a consequence of lifelong exposure to UV radiation,” Theresa Steeb, MPH, of the department of dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University


Tuesday, August 17th, 2021

Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan

Biologic therapies demonstrated improved morbidity and mortality outcomes compared with oral agents and steroids in patients with generalized pustular psoriasis, according to a study. “Because generalized pustular psoriasis (GPP) is uncommon, there are few studies reporting treatments and outcomes for large numbers of patients,” Hideaki Miyachi, MD, PhD, of the department of dermatology at the